Mouse Monoclonal Antibodies Targeting SARS-CoV-2 Nucleocapsid Protein

Opportunity

Available for Licensing and Collaboration

Inventors

Brian Geiss
Tony Schountz
James Terry

At A Glance 

Researchers at Colorado State University have developed several mouse monoclonal antibodies targeting the SARS-CoV-2 nucleocapsid protein.

For more details please contact our office. 

Licensing Director

Steve Foster
Steve.Foster@colostate.edu
970-491-7100

Reference No.: 2020-109

Background

​Coronavirus nucleocapsid protein plays a key role in coating the viral RNA genome during virion formation, and overall pathogenesis. Additionally, the nucleocapsid protein has been used as a diagnostic marker for active coronavirus infection. There are very few antibody reagents currently available that are specific for SARS-CoV-2 nucleocapsid, as most monoclonal antibodies that are commercially available were generated against SARS-CoV nucleocapsid protein and are cross-reactive for SARS-CoV-2 nucleocapsid.

Technology Highlights
  • Clones were screened by ELISA for reactivity towards recombinant SARS-CoV-2 nucleocapsid protein, counter screened against bacterial lysates and heterologous 6xHis-tagged proteins
  • Top 18 clones were tested for efficacy in Western blot analysis with recombinant SARS-CoV-2 nucleoprotein as well as SARS-CoV-2 infected cell lysate
  • Clones are currently being tested for activity in immunofluorescene and immunohistochemistry, and sandwich ELISA assays.
Benefits/Applications
  • Antibodies specifically target SARS-CoV-2 nucleocapsid
  • Nucleocapsid protein is a diagnostic marker for active coronavirus infection
  • Application in ELISA assays, reducing/denatured western blots, immunofluorescence assays, sandwich ELISAs, gene sequences, and others

Last updated: June 2020

Add keywords or various names of inventors here (text is hidden)